{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Trisomie : Questions médicales les plus fréquentes",
"headline": "Trisomie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Trisomie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-15",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Trisomie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aneuploïdie",
"url": "https://questionsmedicales.fr/mesh/D000782",
"about": {
"@type": "MedicalCondition",
"name": "Aneuploïdie",
"code": {
"@type": "MedicalCode",
"code": "D000782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.700.131"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Trisomie",
"alternateName": "Trisomy",
"code": {
"@type": "MedicalCode",
"code": "D014314",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Chih-Ping Chen",
"url": "https://questionsmedicales.fr/author/Chih-Ping%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan; Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan; Department of Biotechnology, Asia University, Taichung, Taiwan; School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan; Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwan; Department of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: cpc_mmh@yahoo.com."
}
},
{
"@type": "Person",
"name": "Fang-Tzu Wu",
"url": "https://questionsmedicales.fr/author/Fang-Tzu%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan."
}
},
{
"@type": "Person",
"name": "Wayseen Wang",
"url": "https://questionsmedicales.fr/author/Wayseen%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan; Department of Bioengineering, Tatung University, Taipei, Taiwan."
}
},
{
"@type": "Person",
"name": "Schu-Rern Chern",
"url": "https://questionsmedicales.fr/author/Schu-Rern%20Chern",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan."
}
},
{
"@type": "Person",
"name": "Peih-Shan Wu",
"url": "https://questionsmedicales.fr/author/Peih-Shan%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Gene Biodesign Co. Ltd, Taipei, Taiwan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36088952",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2352-4642(22)00245-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.",
"datePublished": "2023-10-19",
"url": "https://questionsmedicales.fr/article/37873026",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03085759231203019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36145549",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/pharmaceutics14091801"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).",
"datePublished": "2024-07-14",
"url": "https://questionsmedicales.fr/article/39029359",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lungcan.2024.107894"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.",
"datePublished": "2024-08-20",
"url": "https://questionsmedicales.fr/article/39228724",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2024.08.20.24312311"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Ploïdies",
"item": "https://questionsmedicales.fr/mesh/D011003"
},
{
"@type": "ListItem",
"position": 4,
"name": "Aneuploïdie",
"item": "https://questionsmedicales.fr/mesh/D000782"
},
{
"@type": "ListItem",
"position": 5,
"name": "Trisomie",
"item": "https://questionsmedicales.fr/mesh/D014314"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Trisomie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Trisomie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Trisomie",
"description": "Comment diagnostiquer la trisomie ?\nQuels tests sont utilisés pour la trisomie 21 ?\nÀ quel âge faire un dépistage de trisomie ?\nQuels signes indiquent une trisomie ?\nLa trisomie peut-elle être détectée à la naissance ?",
"url": "https://questionsmedicales.fr/mesh/D014314?mesh_terms=Probability&page=276#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Trisomie",
"description": "Quels sont les symptômes de la trisomie 21 ?\nLa trisomie affecte-t-elle le développement intellectuel ?\nQuels problèmes de santé sont associés à la trisomie ?\nLes symptômes varient-ils selon le type de trisomie ?\nY a-t-il des signes physiques spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D014314?mesh_terms=Probability&page=276#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Trisomie",
"description": "Peut-on prévenir la trisomie ?\nQuels conseils pour les femmes enceintes ?\nLe vieillissement parental influence-t-il la trisomie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes tests génétiques peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D014314?mesh_terms=Probability&page=276#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Trisomie",
"description": "Quels traitements sont disponibles pour la trisomie ?\nLa chirurgie est-elle nécessaire pour la trisomie ?\nComment gérer les problèmes de santé liés à la trisomie ?\nY a-t-il des médicaments pour la trisomie ?\nLes thérapies alternatives sont-elles efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D014314?mesh_terms=Probability&page=276#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Trisomie",
"description": "Quelles sont les complications de la trisomie 21 ?\nLa trisomie augmente-t-elle le risque de leucémie ?\nY a-t-il des complications à long terme ?\nLes complications varient-elles selon le type de trisomie ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014314?mesh_terms=Probability&page=276#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Trisomie",
"description": "Quels sont les facteurs de risque de la trisomie ?\nL'exposition à des toxines influence-t-elle la trisomie ?\nLes maladies génétiques augmentent-elles le risque ?\nLe mode de vie influence-t-il le risque de trisomie ?\nLes traitements de fertilité augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014314?mesh_terms=Probability&page=276#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la trisomie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests génétiques, comme l'amniocentèse ou le test de dépistage prénatal."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la trisomie 21 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le dépistage sérique et l'échographie, suivis d'une amniocentèse si nécessaire."
}
},
{
"@type": "Question",
"name": "À quel âge faire un dépistage de trisomie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage est recommandé dès le premier trimestre de la grossesse, surtout après 35 ans."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une trisomie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies à l'échographie, des marqueurs biochimiques anormaux ou des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "La trisomie peut-elle être détectée à la naissance ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines caractéristiques physiques peuvent indiquer une trisomie à la naissance."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la trisomie 21 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent un retard de développement, des traits faciaux distinctifs et des problèmes de santé."
}
},
{
"@type": "Question",
"name": "La trisomie affecte-t-elle le développement intellectuel ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la trisomie peut entraîner un retard mental et des difficultés d'apprentissage."
}
},
{
"@type": "Question",
"name": "Quels problèmes de santé sont associés à la trisomie ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des problèmes cardiaques, des troubles de la vue et des problèmes immunitaires sont fréquents."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de trisomie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon qu'il s'agit de trisomie 21, 18 ou 13."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes physiques spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traits comme un cou court, des yeux en amande et une langue protrusive sont typiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la trisomie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention, mais le dépistage prénatal peut aider à la détection."
}
},
{
"@type": "Question",
"name": "Quels conseils pour les femmes enceintes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, éviter l'alcool et consulter régulièrement un médecin."
}
},
{
"@type": "Question",
"name": "Le vieillissement parental influence-t-il la trisomie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé de la mère augmente le risque de trisomie, notamment la trisomie 21."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de trisomie peuvent augmenter le risque de récurrence."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques de trisomie chez les futurs parents."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la trisomie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie physique, l'orthophonie et un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle nécessaire pour la trisomie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Parfois, une chirurgie est nécessaire pour corriger des malformations congénitales."
}
},
{
"@type": "Question",
"name": "Comment gérer les problèmes de santé liés à la trisomie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et des soins spécialisés sont essentiels pour gérer les problèmes de santé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments pour la trisomie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de médicaments spécifiques, mais des traitements symptomatiques peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "Les thérapies alternatives sont-elles efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent aider, mais elles ne remplacent pas les soins médicaux traditionnels."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la trisomie 21 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des problèmes cardiaques, des troubles de la vue et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "La trisomie augmente-t-elle le risque de leucémie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants atteints de trisomie 21 ont un risque accru de développer une leucémie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications à long terme peuvent inclure des problèmes de santé mentale et des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de trisomie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon qu'il s'agit de trisomie 21, 18 ou 13."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et des soins appropriés peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de la trisomie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge maternel avancé, des antécédents familiaux et certaines anomalies chromosomiques."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines influence-t-elle la trisomie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'exposition à des toxines environnementales pourrait augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques dans la famille peuvent accroître le risque de trisomie."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de trisomie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire certains risques, mais ne prévient pas la trisomie."
}
},
{
"@type": "Question",
"name": "Les traitements de fertilité augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines techniques de procréation assistée peuvent être associées à un risque accru de trisomie."
}
}
]
}
]
}
Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ...
In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig...
Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4...
An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass...
The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....
This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...
The World Health Organization recommends pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. The aim of this analysis is to quantify the individual risk of HIV infect...
The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi...
This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan....
In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ...
These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...
Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo...
Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander...
Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ...
This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba...
This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....
Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena...
WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha...
This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco...
ISRCTN11434567 . Registered on 7 June 2021....